Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy

A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer

(2015) Frederick H. Wilson et al.   CANCER CELL

Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma

(2015) Ramona Crescenzo et al.   CANCER CELL

Novel ALK inhibitors in clinical use and development

(2015) Chaitanya Iragavarapu et al.   Journal of Hematology & Oncology

S100A4 and its role in metastasis – simulations of knockout and amplification of epithelial growth factor receptor and matrix metalloproteinases

(2015) Antoine Buetti-Dinh et al.   Molecular BioSystems

S100A4 and its role in metastasis – computational integration of data on biological networks

(2015) Antoine Buetti-Dinh et al.   Molecular BioSystems

Transcriptional plasticity promotes primary and acquired resistance to BET inhibition

(2015) Philipp Rathert et al.   NATURE

BET inhibitor resistance emerges from leukaemia stem cells

(2015) Chun Yew Fong et al.   NATURE

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors

(2015) Monika A. Davare et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK

(2015) Phillip B. Murray et al.   Science Signaling

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK

(2015) Phillip B. Murray et al.   Science Signaling

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer

(2015) Hideko Isozaki et al.   Cancers

Selective inhibitors of the Janus kinase Jak3—Are they effective?

(2014) Gebhard Thoma et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

(2014) Ho-June Lee et al.   CANCER CELL

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

(2014) Carlo Gambacorti Passerini et al.   JNCI-Journal of the National Cancer Institute

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

STAT inhibitors for cancer therapy

(2013) Muhammad Furqan et al.   Journal of Hematology & Oncology

Malignant Transformation of CD4+ T Lymphocytes Mediated by Oncogenic Kinase NPM/ALK Recapitulates IL-2-Induced Cell Signaling and Gene Expression Reprogramming

(2013) M. Marzec et al.   JOURNAL OF IMMUNOLOGY

ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intratumoral Heterogeneity for Molecular Drivers

(2013) Dara L. Aisner et al.   MOLECULAR CANCER RESEARCH

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

(2013) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug Resistance Missense Mutations in Cancer Are Subject to Evolutionary Constraints

(2013) Ran Friedman   PLoS One

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins

(2013) M. A. Davare et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

(2012) J Tanizaki et al.   BRITISH JOURNAL OF CANCER

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

(2012) Jasleen Randhawa et al.   Journal of Hematology & Oncology

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

(2012) R. Katayama et al.   Science Translational Medicine

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Anaplastic lymphoma kinase in human cancer

(2011) Antonella Barreca et al.   JOURNAL OF MOLECULAR ENDOCRINOLOGY

Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy

(2010) E. Ardini et al.   CANCER LETTERS

Oncogenic mutations of ALK in neuroblastoma

(2010) Seishi Ogawa et al.   CANCER SCIENCE

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

(2010) Young Lim Choi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of ALK Signaling for Cancer Therapy

(2009) Y. P. Mosse et al.   CLINICAL CANCER RESEARCH

The Anaplastic Lymphoma Kinase Controls Cell Shape and Growth of Anaplastic Large Cell Lymphoma through Cdc42 Activation

(2008) Chiara Ambrogio et al.   CANCER RESEARCH

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia

(2008) Elizabeth Kudlacz et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Activating mutations in ALK provide a therapeutic target in neuroblastoma

(2008) Rani E. George et al.   NATURE

Oncogenic mutations of ALK kinase in neuroblastoma

(2008) Yuyan Chen et al.   NATURE

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

(2008) Isabelle Janoueix-Lerosey et al.   NATURE